Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data

Table 2 Medications for pulmonary arterial hypertension used by all PH-COPD patients and by RHC and PFT subgroups

Medication	All PH-COPD^a (N = 25,975)	RHC^a (N = 2325)	PFT^a (N = 2995)
Any PAH medication	643 (100%)	257 (100%)	58 (100.0)
Endothelin receptor antagonist	195 (30.3%)	106 (41.2%)	19 (32.8%)
PDE5 inhibitor	540 (84.0%)	214 (83.3%)	51 (87.9%)
Prostacyclin receptor agonist	30 (4.7%)	19 (7.4%)	5 (8.6%)
Prostacyclin analog	24 (3.7%)	13 (5.1%)	3 (5.2%)
Soluble guanylate cyclase stimulator	37 (5.8%)	20 (7.8%)	3 (5.2%)

PAH, pulmonary arterial hypertension; PFT, pulmonary function test; PH, pulmonary hypertension; RHC, right-heart catheterization
^aThe denominators for the percentages are the Ns with any PAH medication

ISSN: 1471-2466